# A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

> **NCT06706076** · PHASE1,PHASE2 · RECRUITING · sponsor: **BlossomHill Therapeutics** · enrollment: 266 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** BH-30643
- **DRUG:** BH-30643

## Key facts

- **NCT ID:** NCT06706076
- **Lead sponsor:** BlossomHill Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-09
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06706076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06706076, "A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06706076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*